Skip to main content
TipRanks
Go Ultimate75% OFF

Nectar Lifesciences Ltd. (NECLIFE) AI Stock Analysis

1 Followers
IN:NECLIFE

Nectar Lifesciences Ltd.

(NSE:NECLIFE)

Select Model
Rating:48Neutral
Price Target:INR 10.50▼(-2.14% Downside)
Action:reiterated
Date:08/27/26

The score is primarily weighed down by weak financial performance, highlighted by FY2026’s collapse in revenue, large losses, and significant cash burn that elevate funding and operational risk. Technicals provide some offset due to positive short-term momentum (price above key short-term averages and positive MACD), but overbought readings and a still-weak longer-term trend limit that support. Valuation remains unattractive due to negative earnings (negative P/E).

Positive Factors
Diversified pharmaceutical platformExposure to APIs, finished formulations, and contract services gives Nectar Lifesciences multiple ways to participate in pharmaceutical demand. This broader platform can support customer diversification and allow the company to balance product and service revenue over the medium term.
Negative Factors
Severe revenue disruptionRevenue falling to zero alongside very large losses represents a severe disruption to the company’s operating base. Unless activity is restored, the collapse undermines scale, customer continuity, and the ability to absorb fixed costs, making earnings recovery highly uncertain over the next several quarters.

Nectar Lifesciences Ltd. (NECLIFE) vs. iShares MSCI India ETF (INDA)

-40%-20%0%20%40%60%80%IN:NECLIFE-21.96%INDA-5.86%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
INR 2.07B
Dividend Yield
―
Average Volume (3M)
28.82K
Price to Earnings (P/E)
-0.9
Beta (1Y)
1.26
Revenue Growth
-99.85%
EPS Growth
78.93%
Country
India
Employees
111
Sector
General
Sector Strength
55
Industry
Drug Manufacturers - Specialty & Generic

Nectar Lifesciences Ltd. Business Overview & Revenue Model

Company Description

Nectar Lifesciences Limited, established in Chandigarh, India, in 1995, operates as a global pharmaceutical company involved in the production and distribution of medicinal products. The firm delivers extensive contract research and manufacturing ser...

How the Company Makes Money

Nectar Lifesciences Ltd. makes money primarily by selling pharmaceutical products to customers (typically including other pharmaceutical companies, distributors, and institutional buyers depending on the product category). Key revenue streams general...

Nectar Lifesciences Ltd. Financial Statement Overview

Summary

Overall financial strength is weak: FY2025 returned to meaningful losses after a brief FY2024 improvement, and FY2026 shows a severe disruption with revenue collapsing to zero alongside very large net losses. Cash flow also deteriorated sharply in FY2026 with heavy negative operating/free cash flow, raising near-term liquidity risk, even though leverage was historically moderate and equity remained positive.

Income Statement

18Very Negative

Balance Sheet

42Neutral

Cash Flow

15Very Negative
Financial statement breakdown
BreakdownTTMMar 2026Jun 2025Mar 2024Mar 2023Mar 2022
Income Statement
Total Revenue74.43M20.11M16.70B16.84B15.24B16.69B
Gross Profit-567.25M-590.34M3.02B4.82B579.91M2.99B
EBITDA83.68M-289.51M-245.66M1.69B994.97M1.61B
Net Income-2.45B-2.93B-1.14B49.95M-241.83M250.47M
Balance Sheet
Total Assets06.22B20.47B21.91B21.89B23.91B
Cash, Cash Equivalents and Short-Term Investments1.25B1.25B272.63M203.01M178.94M182.35M
Total Debt005.82B6.36B7.54B8.60B
Total Liabilities-5.82B393.11M10.91B11.22B11.25B13.03B
Stockholders Equity5.82B5.82B9.56B10.69B10.65B10.88B
Cash Flow
Free Cash Flow1.44B-3.61B1.26B1.95B1.04B700.35M
Operating Cash Flow1.53B-3.49B1.69B2.25B1.34B950.05M
Investing Cash Flow-82.31M12.08B-419.30M-170.25M517.04M166.44M
Financing Cash Flow-1.58B-7.67B-1.28B-2.05B-1.86B-1.19B

Nectar Lifesciences Ltd. Technical Analysis

Technical Analysis SentimentPositive
Last Price10.73

Price Trends

50DMA10.84Negative
100DMA10.96Negative
200DMA11.59Negative

Market Momentum

MACD-0.09Negative
RSI55.39Neutral
STOCH65.55Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:NECLIFE, the sentiment is Positive. The current price of 10.73 is above the 20-day moving average (MA) of 10.45, below the 50-day MA of 10.84, and below the 200-day MA of 11.59, indicating a neutral trend. The MACD of -0.09 indicates Negative momentum. The RSI at 55.39 is Neutral, neither overbought nor oversold. The STOCH value of 65.55 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:NECLIFE.

Nectar Lifesciences Ltd. Peers Comparison

Overall Rating

UnderperformOutperform
Sector (55)

Financial Indicators

IN:NECLIFE against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
IN:GRANULESIN:GRANULES72OutperformINR 201.72B28.17―0.21%21.75%36.70%
IN:IOLCPIN:IOLCP72OutperformINR 59.18B29.23―0.50%26.76%75.41%
IN:HIKALIN:HIKAL61NeutralINR 27.45B-559.13―0.27%8.93%-149.51%
IN:NEULANDLABIN:NEULANDLAB60NeutralINR 270.48B59.82―0.16%50.46%88.44%
Sector *55Neutral$6.65B3.83-15.92%6.20%10.91%7.18%
IN:SOLARAIN:SOLARA50NeutralINR 33.20B88.62――27.30%456.80%
IN:NECLIFEIN:NECLIFE48NeutralINR 2.08B-0.93――-99.85%78.93%

* General Sector Average

Performance Comparison

0%50%100%IN:NECLIFEIN:GRANULESIN:HIKALIN:IOLCPIN:NEULANDLABIN:SOLARADec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
IN:NECLIFE and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
IN:NECLIFENectar Lifesciences Ltd.10.73-3.91-26.71%
IN:GRANULESGranules India Limited814.05253.7745.29%
IN:HIKALHikal Limited222.60-10.59-4.54%
IN:IOLCPIOL Chemicals & Pharmaceuticals Ltd.201.60107.48114.19%
IN:NEULANDLABNeuland Laboratories Ltd.21081.703757.6221.69%
IN:SOLARASolara Active Pharma Sciences Ltd.690.60115.4520.07%

Nectar Lifesciences Ltd. Corporate Events

Nectar Lifesciences Issues Revised AGM Proceedings, Receives Clean Audit for FY 2025-26

Sep 19, 2026

Nectar Lifesciences has issued revised proceedings for its 31st Annual General Meeting after correcting an inadvertent error in the cut-off date, reaffirming its adherence to SEBI listing regulations. The AGM was conducted on September 18, 2026 via v...

Nectar Lifesciences Publishes Q1 FY2026 Results in Press and Online

Aug 15, 2026

Nectar Lifesciences Ltd. has released its unaudited financial results for the quarter ended June 30, 2026, and circulated them through national daily Business Standard and Punjabi newspaper Desh Sewak. The company has also made detailed consolidated...

Nectar Lifesciences to Relocate Corporate Office Within Chandigarh Industrial Hub

Aug 15, 2026

The board of directors of Nectar Lifesciences Ltd. has approved the relocation of the company’s corporate office within Chandigarh’s Industrial Area Phase 1, moving from Plot No. 110 to the West Wing of Godrej Eternia, Plot No. 70, with effect from S...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Aug 27, 2026